Results 111 to 120 of about 4,766,757 (295)
A future cities survey research design for policy analysis [PDF]
, 1976 Kenneth L. Kraemer +4 more
openalex +1 more source
Molecular Oncology, EarlyView.mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).
Jesús García‐Castillo +8 more
wiley +1 more source
1) RESEARCH ON SHELL FOUNDATIONS EXPERIMENTS, THEORY, DESIGN, CONSTRUCTION, AND APPLICATIONS
, 1949 Kazuo Minami
openalex +2 more sources
Molecular Oncology, EarlyView.The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine +10 more
wiley +1 more source
Design of Research Reactors, Especially About a Water Boiler Type Reactor
, 1956 Masakichi MATSUMOTO, Schoichi HIRAYAMA
openalex +2 more sources
Design Status of a Separated-Sector Cyclotron Booster Accelerator for the Holifield Heavy Ion Research Facility [PDF]
, 1977 J.A. Martin +5 more
openalex +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
The association between research design and the perceived treatment effectiveness: a cross-sectional study. [PDF]
Front Med (Lausanne), 2023 Bralić N, Buljan I.
europepmc +1 more source
240) Experimental Research on Ultimate Load Design of Shell Roofs (Part 4)(Civil Engineering)
, 1956 Wataru Kato, Akira Enami
openalex +2 more sources
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source